SAN FRANCISCO, December 13 /PRNewswire/ -- Synosia Therapeutics today
announced the appointment of Antony Blanc, Ph.D., as the company's new
chief business officer, effective immediately.
Dr Blanc, who will serve as head of Synosia's office in Basel,
Switzerland, joins from Syngenta, where he created and led the
biopharmaceuticals business unit. A molecular biologist by training and an
experienced biotech entrepreneur, Dr. Blanc helped biotech and pharma
clients with R&D, commercial and strategy issues as associate partner with
the business consultants McKinsey & Company.
"With a strong entrepreneurial flair in biotech and expertise in both
science and business, Antony Blanc brings together the skills we need to
lead our increasingly important presence in Switzerland," said Synosia
Chief Executive Officer and President Dr. Ian Massey. "Our three
pharmaceutical partners are based in Basel and this appointment will give
us the leadership we need in Europe to meet our ambitious goals for 2008,
including the start of four phase II trials."
"Synosia has a broad clinical-stage portfolio with several advanced
molecules, highly experienced leaders, a well-aligned and strong investor
base and a grounding in both the US and in Switzerland. I look forward to
building on this promising combination to create a leading CNS-focused
specialty pharma company" said Blanc.
Antony Blanc replaces Herve Girsault M.B.A., who will remain on
Synosia's board of directors and continue to act as a key business advisor
to the company.
About Synosia Therapeutics
Synosia Therapeutics develops and intends to commercialize innovative
and clinically differentiated products for unmet medical needs in
psychiatry and neurology. The privately-owned company is developing six
clinical-stage compounds acquired through key partnerships with Novartis,
Roche and Syngenta, including two marketed drugs that will be tested in new
indications, extending their reach into new therapeutic areas with combined
sales potential in excess of US$2.5 billion. Synosia has offices in Basel,
Switzerland, and South San Francisco, CA.
Synosia Therapeutics has raised US$32.5 million funding from Versant
Ventures (Menlo Park, CA), Abingworth Management (London), 5AM Ventures
(Menlo Park, CA) and Novo A/S (Copenhagen, Denmark). For more information,
SOURCE Synosia Therapeutics